U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07473843) titled 'Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia' on March 11.
Brief Summary: This study will evaluate the efficacy and safety of zodasiran subcutaneous (sc) injection in participants 12 to =116 milligrams per deciliter (mg/dL) on maximally tolerated lipid-lowering therapy.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Homozygous Familial Hypercholesterolemia
Intervention:
DRUG: Zodasiran
By sc injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Arrowhead Pharmaceuticals
Published by HT Digital Content Services with permission from Health Daily Digest....